Organizing Committee

Committee Members

Photo of Marie Bleakley

Marie Bleakley, M.D., Ph.D., M.MSC.

Dr. Bleakley is a pediatric hematologist-oncologist who specializes in hematopoietic (blood-forming) stem cell transplantation and T cell immunotherapy for patients with leukemia and other blood cancers.

Photo of Aude G. Chapuis

Aude G. Chapuis, M.D.

Dr. Chapuis is an expert in blood stem cell transplantation and immunotherapy. She cares for patients undergoing these treatments and leads clinical trials of new immunotherapies in which patients receive immune cells called T cells that can detect and destroy diseased cells.

Photo of Geoff Hill

Geoffrey Hill, M.D., FRACP, FRCPA

Dr. Hill is a physician-scientist who specializes in blood stem cell transplantation. He is one of the top authorities on the transplant complication known as graft-vs.-host disease, or GVHD.

Photo of Hans-Peter Kiem

Hans-Peter Kiem, M.D., Ph.D.

Dr. Kiem is a world-renowned pioneer in stem-cell and gene therapy and in the development of new gene-editing technologies. 

Photo of David G. Maloney

David G. Maloney, M.D., Ph.D.

Dr. Maloney develops new treatments for patients with lymphomas, leukemias and myeloma as well as other cancers. He is widely recognized as an expert in treating people with these cancers. 

Photo of Marco Mielcarek

Marco Mielcarek, M.D.

Dr. Mielcarek is the medical director of the Adult Blood and Marrow Transplant Program at Seattle Cancer Care Alliance and Fred Hutch.

Photo of Filippo Milano

Filippo Milano, M.D., Ph.D.

Dr. Milano is a physician-scientist whose research is focused on the use of umbilical cord blood as a source of stem cells for transplantation to treat blood cancers. 

Photo of Stanley Riddell

Stanley Riddell, M.D.

Dr. Riddell is a world leader in developing immunotherapies, which harness the power of the immune system to fight cancers and dangerous infections.

Photo of Brenda Sandmaier

Brenda Sandmaier, M.D.

Dr. Sandmaier’s goal is to extend the benefits of transplant immunotherapy to a broader range of patients, including hematopoietic cell transplant patients who are older or have medical complications, and those who don’t have donors with complete genetic matches.